Chemomab Therapeutics Ltd. (CMMB)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.5400 |
| Open | 1.4800 |
| Bid | 1.4800 x 1100 |
| Ask | 1.5300 x 1400 |
| Day's Range | 1.4800 - 1.5900 |
| 52 Week Range | 1.3750 - 5.3500 |
| Volume | |
| Avg. Volume | 894,601 |
| Market Cap | 17.569M |
| Beta (5Y Monthly) | -0.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3400 |
| Earnings Date | Mar 31, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.33 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CMMB
Related Research
- Chemomab Therapeutics Ltd.NEO: What does Argus have to say about NEO?NEOGENOMICS INC has an Investment Rating of HOLD; a target price of $52.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.RatingFair ValueEconomic Moat2 years agoArgus Research
- PR Newswire
Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will provide a Corporate Update on Monday, April 17, 2023, at 8:00 am Eastern Time. This event replaces the webcast and call originally scheduled for March 31, 2023.
- PR Newswire
Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will discuss its fourth quarter and full-year 2022 financial results and provide a business update on Friday, March 31, 2023, at 8:00 am Eastern Time.
- PR Newswire
Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday March 15, 2023. The conference format this year is virtual.
